"Intellectual property" and indigenous peoples in the international human rights arena

This presentation was given as part of the Expert Seminar on Indigenous Cultures and Languages in collaboration with the UN by Professor Graham Dutfield from the University of Leeds. The seminar, hosted at Brunel University, took place on the 8th and 9th March 2012 and was organised by Brunel Law School's Human Rights Research Centre. The initiative, fronted by Dr Alexandra Xanthaki of Brunel Law School, represents a positive example of how academia, the civil society and the international community can come together with vulnerable groups to help the regain their rights

Intellectual Property Rights and the Ascent of Proprietary Innovation in Agriculture

Biological innovations in agriculture did not enjoy protection by formal intellectual property rights (IPRs) for a long time, but the recent trend has been one of considerable broadening and strengthening of these rights. We document the nature of these IPRs and their evolution, and provide an assessment of their impacts on innovation. We integrate elements of the institutional history of plant IPRs with a discussion of the relevant economic theory and a review of applicable empirical evidence. Throughout, we highlight how the experience of biological innovation mirrors, or differs from, the broader literature on IPRs and innovation. We conclude with some considerations on the relation between IPRs and market structure and the pricing of proprietary inputs in agricultur

Intergenerational justice: a framework for addressing intellectual property rights and climate change

At first blush, one may wonder what contribution normative theory can make to what seems to be such a technical/political issue as the role of intellectual property rights (IPRs) in the global climate change regime. There are two answers to this. Firstly, as eloquently put by Joe Bowersox,“... normative theory… can be a powerful diagnostic tool for evaluating public policy; it can act as an altimeter, if you will, that checks the thinness of the theoretical air surrounding a particular policy mountain or molehill, telling us whether there is enough oxygen present to support political life. Sometimes theory may even suggest that we try an alternative, less precipitous policy pass by which to cross to the other side.” Conceptions about justice - can provide a valuable framework in terms of ensuring that policy prescriptions are well directed, particularly given that economic policy discourse can bury ethical assumptions. This broader picture, can provide a valuable point of reference in the highly technical debates relating to intellectual property rights and climate change. A second reason for turning to normative theory is the reality that environmental treaties will not be agreed to without at least overlapping conceptions of fairness. This provides a practical motivation for interrogating more deeply justice discourses involved in the climate change negotiations. To the extent that the current global climate regime is inadequate, shared understandings of justice are a crucial precondition for reforming and making more effective the current climate change regime

The international biotrade, conservation and intellectual property rights

Available from British Library Document Supply Centre-DSC:D213471 / BLDSC - British Library Document Supply CentreSIGLEGBUnited Kingdo

That High Design of Purest Gold: A Critical History of the Pharmaceutical Industry, 1880-2020

This book is a history of medicines and the commercial actors that make and sell them, covering the 140 years since the modern pharmaceutical industry came into being. It is written in a lively and accessible way, aiming at a general audience that combines historical narrative with fascinating case studies on drug discovery and commercialization, from the rat poison that became warfarin, to a cardiovascular treatment that was turned into Viagra. In a non-partisan way it also examines some of the less noble manifestations of corporate behavior, concluding with an agenda for reform. It is hard to think of anything nobler than to bring to the world a medicine that saves lives. And over 140 years of history, the pharmaceutical industry has produced a range of remarkable products, albeit typically with external scientific and financial support. Making medicines is a very big and profit-driven business, and the industry does not always make the right products for the right people, or at the right prices. The industry wields immense power over lives and economies. How has it risen to this position of dominance? Are the interests of the industry and the public in balance? What should we admire about the industry? What should we criticise and seek to change? The importance of this book lies in the fact that we are all stakeholders in this industry whether or not we own shares, so we all need answers to these questions